MTBR‐tau243 biomarker specifically identifies mixed 3R/4R tauopathies
MTBR-tau243 biomarker specifically reflects the accumulation of aggregated insoluble tau in mixed 3R/4R tauopathies including AD, CTE and FTLD-MAPT with R406W mutation while not in 4R (CBD, PSP, AGD) or 3R primary tauopathies (PiD). MTBR-tau243 biomarker can stage mixed 3R/4R tauopathies, aiding clinicians in determining the underlying cause of cognitive impairment and monitoring the efficacy of tau-targeted therapies. Reference: [1] Horie, K., et al. Nat Med 29, 1954-1963 (2023). [2] Horie, K., et al. Nat Med (2025). https://doi.org/10.1038/s41591-025-03617-7.
Authors
- Chihiro Sato (ORCID: https://orcid.org/0000-0002-7639-8727)
- Salvatore Spina (ORCID: https://orcid.org/0000-0003-3570-9143)
- L. VandeVrede
- Ross W. Paterson (ORCID: https://orcid.org/0000-0001-9372-3635)
- Rama K. Koppisetti (ORCID: https://orcid.org/0000-0002-7539-4572)
- Nupur Ghoshal (ORCID: https://orcid.org/0000-0002-6680-6731)
- Kanta Horie (ORCID: https://orcid.org/0000-0001-7736-2614)
- Adam L. Boxer
- Randall J. Bateman
Institutions
- University of California, San Francisco (US)
- Washington University in St. Louis (US)
- National Hospital for Neurology and Neurosurgery (GB)
- Eisai (United States) (US)
- University College London (GB)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108254
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00